[Study of the current status of Schistosoma haematobium infection in the European Union. An approach to the possible risk in Spain]. / Estudio de la situación actual de la infección por Schistosoma haematobium en la Unión Europea. Una aproximación al posible riesgo en España.

OBJECTIVE: In Europe, urogenital schistosomiasis was not endemic, however in 2014 the first cases of a European autochthonous infection outbreak appeared in Corsica (France). In this work a search and description of cases, both import and native urogenital schistosomiasis, published in the European Union (EU) during the last 20 years was made. In addition, a qualitative risk assessment in Spain was carried out. METHODS: A bibliographic search of European Union published cases over the last 20 years (1997-2017) was performed using PubMed. Works that evidenced the presence of intermediate hosts Bulinus truncatus and Planorbarius metidjensis in our country were searched in PubMed, ResearchGate and Google Scholar. Finally, a risk assessment of urogenital schistosomiasis in Spain using the 2011 ECDC guide was made. RESULTS: 481 cases in the EU were found. 328 were imported and 152 autochthonous. All from the autochthonous cases were focused in Corsica, where people from different nationalities got sicked. The presence of two potential host species was documented in different locations of our geography. The result of the risk assessment in Spain was low risk. CONCLUSIONS: Although the risk assessment in Spain was low risk, several factors as the presence of intermediate hosts in Spain, the increase on migratory flows, and the role that the S. haematobium-bovis hybrid had in the outbreak of Corsica, must alert community and health authorities about the possibility that autochthonous cases in our country appear.

OBJETIVO: En Europa no era endémica la esquistosomiasis urogenital, sin embargo en 2014 aparecieron en Francia los primeros casos de un brote de infección autóctona europea. En este trabajo se hace una búsqueda y descripción de casos de esquistosomiasis urogenital, tanto importados como autóctonos, publicados en la Unión Europea (UE) durante los últimos 20 años. Además se realiza una evaluación cualitativa del riesgo en España. METODOS: Se realizó una búsqueda bibliográfica en PubMed de casos publicados en la UE durante los últimos 20 años (1997-2017). Se buscaron trabajos en PubMed, ResearchGate y Google Académico que evidenciasen la presencia hospedadores intermediarios Bulinus truncatus y Planorbarius metidjensis en nuestro país. Finalmente se evaluó el riesgo de esquistosomiasis urogenital en España aplicando la guía del ECDC de 2011. RESULTADOS: Se hallaron 481 casos en la UE, 328 eran importados y 152 autóctonos. En todos los casos autóctonos el foco se localizó en Córcega, donde enfermaron personas de diversas nacionalidades. Se documentó la presencia de dos especies hospedadores potenciales en diversas localizaciones de nuestra geografía. El resultado de la evaluación de riesgo en España fue bajo riesgo. CONCLUSIONES: Si bien el resultado de la evaluación de riesgo en España fue bajo riesgo, factores como la presencia de hospedadores intermediarios, el aumento de los flujos migratorios, y el papel que tuvo el híbrido S. haematobium-bovis en el brote de Córcega, deben poner en sobre aviso a la comunidad médica y las autoridades sanitarias ante la posibilidad de que aparezcan casos autóctonos en nuestro país.

Estudio de la situación actual de la infección por Schistosoma Haematobium en la Unión Europea. Una aproximación al posible riesgo en España / Study of the current status of schistosoma haematobium infection in the European Union. An approach to the possible risk in Spain

Fundamentos. En Europa no era endémica la esquistosomiasis urogenital, sin embargo, en 2014 aparecieron en Francia los primeros casos de un brote de infección autóctona europea. En este trabajo se hace una búsqueda y descripción de casos de esquistosomiasis urogenital, tanto importados como autóctonos, publicados en la Unión Europea (UE) durante los últimos 20 años. Además, se realiza una evaluación cualitativa del riesgo en España. Métodos. Se realizó una búsqueda bibliográfica en PubMed de casos publicados en la UE durante los últimos 20 años (1997-2017). Se buscaron trabajos en PubMed, ResearchGate y Google Académico que evidenciasen la presencia hospedadores intermediarios Bulinus truncatusy Planorbarius metidjensis en nuestro país. Finalmente se evaluó el riesgo de esquistosomiasis urogenital en España aplicando la guía del ECDC de 2011. Resultados. Se hallaron 481 casos en la UE, 328 eran importados y 152 autóctonos. En todos los casos autóctonos el foco se localizó en Córcega, donde enfermaron personas de diversas nacionalidades. Se documentó la presencia de dos especies hospedadores potenciales en diversas localizaciones de nuestra geografía. El resultado de la evaluación de riesgo en España fue bajo riesgo. Conclusiones. Si bien el resultado de la evaluación de riesgo en España fue bajo riesgo, factores como la presencia de hospedadores intermediarios, el aumento de los flujos migratorios, y el papel que tuvo el híbrido S. haematobium-bovis en el brote de Córcega, deben poner en sobre aviso a la comunidad médica y las autoridades sanitarias ante la posibilidad de que aparezcan casos autóctonos en nuestro país

Background. In Europe, urogenital schistosomiasis was not endemic, however in 2014 the first cases of a European auto-chthonous infection outbreak appeared in Corsica (France). In this work a search and description of cases, both import and native urogenital schistosomiasis, published in the European Union (EU) during the last 20 years was made. In addition, a qualitative risk assessment in Spain was carried out. Methods. A bibliographic search of European Union published cases over the last 20 years (1997-2017) was performed using PubMed. Works that evidenced the presence of intermediate hosts Bulinus truncates and Planorbarius metidjensis in our country were searched in PubMed, ResearchGate and Google Scholar. Finally, a risk assessment of urogenital schistosomiasis in Spain using the 2011 ECDC guide was made. Results. 481 cases in the EU were found. 328 were imported and 152 autochthonous. All from the autochthonous cases were focused in Corsica, where people from different nationalities got sicked. The presence of two potential host species was documented in different locations of our geography. The result of the risk assessment in Spain was low risk. Conclusions. Although the risk assessment in Spain was low risk, several factors as the presence of intermediate hosts in Spain, the increase on migratory flows, and the role that the S. haematobium-bovis hybrid had in the outbreak of Corsica, must alert community and health authorities about the possibility that autochthonous cases in our country appear

Recurrencias en infecciones por Clostridium difficile en pacientes con cáncer / Recurrences in Clostridium difficile infections in cancer patients

No disponible

Primer caso de bacteriemia por Sphingomonas anadarae en un paciente con cáncer / First case of bacteremia by Sphingomonas anadarae in an patient with cancer

No disponible

Importancia clínica del análisis molecular del cassette cromosómico SCCmecA en cepas de Staphylococcus aureus resistente a la meticilina / Clinical significance of molecular analysis of the chromosomal cassette SCCmecA in methicillin-resistant strains of Staphylococcus aureus

No disponible

Utilización de procalcitonina y proteína C reactiva como marcadores de infección en la neutropenia febril de pacientes sometidos a trasplante de progenitores hematopoyéticos / Use of procalcitonin and C-reactive protein as infection markers in febrile neutropenic patients undergoing haematopoietic stem cell transplant

INTRODUCCIÓN Y OBJETIVO: La neutropenia es un signo frecuente en los pacientes que van a ser sometidos a trasplante de progenitores hematopoyéticos (TPH). Una complicación importante es la infección favorecida por la inmunodepresión y el grado de neutropenia. El objetivo del estudio es evaluar la utilidad diagnóstica de la procalcitonina (PCT) y de la proteína C reactiva (PCR) en pacientes onco-hematológicos sometidos a quimioterapia y TPH para discriminar la etiología de la fiebre. PACIENTES Y MÉTODOS: Se midieron los valores de PCT y PCR en 30 episodios de neutropenia febril antes del inicio de la quimioterapia, el día de la neutropenia, el día del inicio de la fiebre y los días 1, 2, 3 y 6 postinicio de la fiebre y al fin del episodio. Los episodios fueron clasificados como 5 bacteriemias, 3 infecciones documentadas microbiológicamente, 10 infecciones clínicas y 12 fiebres de origen desconocido. RESULTADOS: Los valores medios de PCT más elevados correspondieron al grupo de pacientes con bacteriemia. Hubo diferencias estadísticamente significativas (p = 0,04) el segundo día tras el inicio de la fiebre. El punto de corte de 0,5 ng/ml mostró una sensibilidad del 66% y una especificidad del 75%. La PCR mostró diferencias estadísticamente significativas los días 1, 2 y 3 postinicio de la fiebre (p = 0,01; p = 0,003 y p = 0,002). El punto de corte de 7,5 mg/dl mostró una sensibilidad del 88% y una especificidad del 58%. CONCLUSIONES: La combinación de PCT y PCR es un método insuficiente para la detección de infección bacteriana y no puede sustituir el correcto diagnóstico clínico y microbiológico

INTRODUCTION AND OBJECTIVE: Neutropenia is a frequent sign in patients who are going to have a haematopoietic stem cell transplant (HSCT).Infection is an important complication in these patients, which is favoured by immunosuppression and the degree of neutropenia. This study aims to evaluate the diagnostic usefulness of procalcitonin (PCT) and C-reactive protein (CRP) in onco-haematological patients undergoing chemotherapy and HSCT to determine the origin of the fever. PATIENTS AND METHODS:PCT and CRP values were measured in 30 episodes of febrile neutropenia: before starting chemotherapy, appearance of neutropenia, onset of fever, days 1, 2, 3 and 6 after the onset of fever, and when the febrile episode ended. The episodes were classified as 5 bacteraemia, 3 microbiologically documented infections, 10 clinical infections, and 12 fevers of unknown origin. RESULTS: The highest PCT mean values corresponded to the group of patients with bacteraemia. Statistically significant differences (P=.04) were found on the second day after the onset of fever. The cut-off point of 0.5ng/ml showed a sensitivity of 66% and a specificity of 75%. PCR results showed statistically significant differences on days 1, 2 and 3 after the onset of fever (P=.01, P=.003, and P=.002, respectively). The cut-off point of 7.5mg/L had a sensitivity of 88% and a specificity of 58%.CONCLUSIONS:The combination of PCT and CRP is an insufficient method to detect bacterial infections and may not replace the proper clinical and microbiological diagnosis (AU)

HE4, Ca125 and ROMA algorithm for differential diagnosis between benign gynaecological diseases and ovarian cancer.

The aim of this study is to evaluate the diagnostic performance of human epididymis protein 4 (HE4), cancer antigen 125 (Ca125) and the risk of ovarian malignancy algorithm (ROMA) in discriminating ovarian cancer from other benign gynaecological diseases. Serum levels of HE4 and Ca125 were measured in 119 women with benign gynaecological diseases, 29 patients with primary ovarian cancer, 32 patients with ovarian cancer on chemotherapy treatment (18 of them with progressive disease), 6 patients treated and free of disease and 32 healthy women. Sensitivity, specificity, positive and negative predictive values and positive and negative likelihood ratios (LR ±) were calculated. Receiver operator characteristic (ROC) curves were constructed, and the areas under the curve (AUC) were calculated. High serum levels for HE4, Ca125 and ROMA were observed in cancer patients. HE4 was elevated in 12.6 %, Ca125 in 21 % and ROMA in 9.2 % in the benign group, but HE4 was not elevated in endometriosis. The AUC values for HE4, Ca125 and ROMA were 0.92, 0.911 and 0.945 respectively. The sensitivity for discriminating ovarian cancer from benign gynaecological diseases was 86.2 % for HE4 and Ca125 and 93.1 % for ROMA. The specificity was 87.4, 78.9 and 90.7 % for HE4, Ca125 and ROMA. The overall positive likelihood ratio (LR+) was 6.84 for HE4, 4.1 for Ca125 and 10.01 for ROMA. In premenopausal women, LR + was 11.86 for HE4, 5.11 for ROMA and 2.02 for Ca125. HE4 might be significant in the differential diagnosis of ovarian cancer. HE4 seems to be superior to Ca125 in terms of diagnostic performance of all premenopausal women. ROMA could help to discriminate in cases with any doubt with a high diagnostic accuracy.

[Use of procalcitonin and C-reactive protein as infection markers in febrile neutropenic patients undergoing haematopoietic stem cell transplant]. / Utilización de procalcitonina y proteína C reactiva como marcadores de infección en la neutropenia febril de pacientes sometidos a trasplante de progenitores hematopoyéticos.

INTRODUCTION AND OBJECTIVE: Neutropenia is a frequent sign in patients who are going to have a haematopoietic stem cell transplant (HSCT). Infection is an important complication in these patients, which is favoured by immunosuppression and the degree of neutropenia. This study aims to evaluate the diagnostic usefulness of procalcitonin (PCT) and C-reactive protein (CRP) in onco-haematological patients undergoing chemotherapy and HSCT to determine the origin of the fever. PATIENTS AND METHODS: PCT and CRP values were measured in 30 episodes of febrile neutropenia: before starting chemotherapy, appearance of neutropenia, onset of fever, days 1, 2, 3 and 6 after the onset of fever, and when the febrile episode ended. The episodes were classified as 5 bacteraemia, 3 microbiologically documented infections, 10 clinical infections, and 12 fevers of unknown origin. RESULTS: The highest PCT mean values corresponded to the group of patients with bacteraemia. Statistically significant differences (P=.04) were found on the second day after the onset of fever. The cut-off point of 0.5ng/ml showed a sensitivity of 66% and a specificity of 75%. PCR results showed statistically significant differences on days 1, 2 and 3 after the onset of fever (P=.01, P=.003, and P=.002, respectively). The cut-off point of 7.5mg/L had a sensitivity of 88% and a specificity of 58%. CONCLUSIONS: The combination of PCT and CRP is an insufficient method to detect bacterial infections and may not replace the proper clinical and microbiological diagnosis.

Raoultella ornithinolytica en infecciones de las vías urinarias. Estudio clínico y microbiológico de una serie de 4 pacientes con neoplasias / Raoultella ornithinolytica in urinary tract infections. Clinical and microbiological study of a series of 4 oncologic patients

No disponible

Paniculitis pancreática como forma de presentación inicial de adenocarcinoma gástrico con metástasis hepáticas / Gastric adenocarcinoma with hepatic metastases presenting as pancreatic panniculitis

El interés del caso reportado surge a raíz de la obtención de un valor de lipasa superior a 7.000 U/l en una paciente con una paniculitis en miembros inferiores de 10 meses de evolución. Se estableció el diagnóstico de paniculitis pancreática, y adenocarcinoma gástrico con metástasis hepáticas, con la peculiaridad de no encontrar afectación clínica ni radiológica del páncreas. Las paniculitis pancreáticas de origen tumoral no pancreático constituyen una rareza, y son un hecho excepcional en la literatura médica consultada. Este es el primer caso de paniculitis pancreática como signo inicial de un cáncer gástrico, con metástasis hepáticas y con mayor supervivencia reportado en la literatura, lo cual hace que su revisión clínica e histológica sea de extraordinario interés(AU)

A patient presenting with a ten month history of progressive lower limb panniculitis was found to have more than 7,000 lipase U/L. Pancreatic panniculitis and gastric adenocarcinoma with liver metastases was diagnosed, despite no clinical or radiological findings of pancreatic disease. Pancreatic panniculitis arising from a non pancreatic primary is extremely rare. To our knowledge, this is the first time pancreatic panniculitis has been reported as the presenting sign of gastric carcinoma with hepatic metastases. It is also the longest survival to be reported to date(AU)